From: Epidermal Growth Factor Receptor and K-RAS status in two cohorts of squamous cell carcinomas
Immuno-reactivity | No. (%) of cases | |||||||
---|---|---|---|---|---|---|---|---|
 | Anal Canal SCC (n = 43) | Tonsil SCC (n = 24) | ||||||
 | - | 1+ | 2+ | 3+ | - | 1+ | 2+ | 3+ |
<5% | 7 (16.3) | 0 | 0 | 0 | 4 (16.7) | 0 | 0 | 0 |
5-25% | 0 | 4 (9.3) | 2 (4.7) | 1 (2.3) | 0 | 6 (25) | 0 | 1 (4.2) |
26-50% | 0 | 0 | 3 (7) | 2 (4.7) | 0 | 2 (8.3) | 1 (4.2) | 0 |
51-75% | 0 | 1 (2.3) | 4 (9.3) | 2 (4.7) | 0 | 2 (8.3) | 1 (4.2) | 2 (8.3) |
>75% | 0 | 2 (4.7) | 3 (7) | 12 (27.9) | 0 | 0 | 2 (8.3) | 3 (12.5) |
Total | 7 (16.3) | 7 (16.3) | 12 (28) | 17 (39.6) | 4 (16.7) | 10 (41.6) | 4 (16.7) | 6 (25) |